BRIM Biotechnology is a pioneering brand that specializes in developing transformative treatments to combat and cure diseases. With a strong focus on translational science, we aim to bring new medicines to patients sooner, ensuring they are affordable and accessible worldwide. Founded in Taiwan in 2013 by a team of seasoned global pharma experts, our company boasts world-leading expertise in translational science.

This has allowed us to rapidly advance several discoveries into the clinic, resulting in the successful spin-out of Ascendo Biotechnology, Inc in 2019. Our pipeline is underpinned by our innovative stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform. This platform has the potential to be effective in multiple therapy areas and indications.

With a strong track record of translating discovery research to the clinic, we are dedicated to identifying and incubating high-potential drug candidates to deliver partner-ready clinical assets. Our mission is to transform patients' lives by advancing promising discoveries into disease-modifying treatments, while our vision is to inspire the next generation of biotech entrepreneurs to bring affordable healthcare innovation to the world. If you are interested in partnering with us, please contact us to explore the possibilities of collaboration